TENSILON (edrophonium chloride) by R-Pharm US. Approved for depression. First approved in 1951.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TENSILON (edrophonium chloride) is an acetylcholinesterase inhibitor administered by injection used to treat depression. The drug works by inhibiting the breakdown of acetylcholine, increasing its availability at the neuromuscular junction and central nervous system. This 1951-approved medication represents a legacy class with limited modern usage.
As a legacy asset approaching loss of exclusivity with minimal commercial activity, positions on this product involve limited growth opportunity and typically small, maintenance-focused teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Working on TENSILON as a pharma professional means managing a legacy injectable asset with minimal growth dynamics and limited career advancement potential. Roles are primarily defensive and focused on compliance, market maintenance, and regulatory stewardship rather than innovation or expansion.
Worked on TENSILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.